RE:RE:RE:Starting to think no news today would be betterMCNA should receive priority review based on this:
U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product
This FDA Fast Track designation means that, when data from the Phase III program becomes available, the Company could expect an expedited review of its Biologics Licensing Application for Urocidin.
https://www.prnewswire.com/news-releases/us-fda-grants-fast-track-designation-for-bioniche-bladder-cancer-product-56050392.html